BridgeMD
Compares treatment options for Plaque Psoriasis
Official title Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov ID: NCT07251998
What this study is testing
What is ICP-332 Tablets?
ICP-332 Tablets is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for plaque psoriasis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- people voluntarily participate in this study and have signed the Informed Consent Form (ICF).
- Male or female people aged ≥ 18 years and ≤ 70 years
- A history of plaque psoriasis for ≥6 months at baseline
- Meet the following three criteria:
- Psoriasis Area and Severity Index (PASI) score ≥12
You likely can't join if
- Diagnosed with non-plaque psoriasis.
- Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
- Presence of clinically serious, progressive, or uncontrolled disease.
- Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
- Pregnant or lactating women.
- The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.
See the full eligibility criteria
- people voluntarily participate in this study and have signed the Informed Consent Form (ICF).
- Male or female people aged ≥ 18 years and ≤ 70 years
- A history of plaque psoriasis for ≥6 months at baseline
- Meet the following three criteria:
- Psoriasis Area and Severity Index (PASI) score ≥12
- Static Physician's Global Assessment (sPGA) score ≥3
- Psoriasis affected Body Surface Area (BSA) ≥10%
- The subject requires systemic treatment and/or phototherapy.
- Diagnosed with non-plaque psoriasis.
- Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
- Presence of clinically serious, progressive, or uncontrolled disease.
- Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
- Pregnant or lactating women.
- The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.